Adimmune Corp
TWSE:4142
Adimmune Corp
Cash from Operating Activities
Adimmune Corp
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Adimmune Corp
TWSE:4142
|
Cash from Operating Activities
NT$100.2m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GenMont Biotech Inc
TWSE:3164
|
Cash from Operating Activities
NT$72.4m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
10%
|
|
E
|
Energenesis Biomedical Co Ltd
TWSE:6657
|
Cash from Operating Activities
-NT$232.8m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
See Also
What is Adimmune Corp's Cash from Operating Activities?
Cash from Operating Activities
100.2m
TWD
Based on the financial report for Mar 31, 2024, Adimmune Corp's Cash from Operating Activities amounts to 100.2m TWD.
What is Adimmune Corp's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-57%
The average annual Cash from Operating Activities growth rates for Adimmune Corp have been -57% over the past three years .